EUVIMEDEUVIMED entdecken
Crossref

Phototherapy for Atopic Dermatitis in the Era of Biologics and JAK Inhibitors: Mechanisms, Protocols, Evidence, and Positioning

Gustavo Almeida-Silva iD, João Ferreira, René Santus, Paulo Filipe

Clinical and Experimental Dermatology · 13.11.2026

DOI: 10.1093/ced/llag478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 13.11.2026. Verfasst von Gustavo Almeida-Silva und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biologics and Janus kinase (JAK) inhibitors have transformed the treatment of atopic dermatitis (AD), but phototherapy remains accessible, relatively inexpensive and free of systemic drug interactions. This narrative review synthesises mechanistic data, clinical trials, real-world studies and emerging evidence on phototherapy alongside targeted systemic therapies. Narrowband ultraviolet B (NB-UVB) and UVA1 can improve pruritus and disease activity in selected patients, although the evidence base is heterogeneous and many trials predate contemporary outcome measures. Retrospective data suggest that patients with moderate, intermittent disease may be more likely to benefit than those with severe, continuously active AD. Small studies of short-cycle NB-UVB added to dupilumab suggest faster early improvement, without a clear adverse-event signal in the limited available datasets; however, durable benefit and the absence of additional toxicity have not been established. Evidence for combining phototherapy with oral JAK inhibitors is largely extrapolated from non-AD settings and remains speculative. Phototherapy therefore retains a role as a selected treatment or adjunct when systemic therapy is unsuitable, undesired or not readily accessible. Proposed stage-specific combination and flare-control strategies should be regarded as hypothesis-generating and require prospective validation before they can be considered standard practice.

Autor:innen und Institutionen

  • Department of Dermatology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
  • Dermatology University Clinic, Faculty of Medicine of the University of Lisbon, Lisbon, Portugal.
  • Investigative Dermatology Unit, Medicine U Lisboa for Health, Clinical Research and Innovation (MUHCRI), Lisbon, Portugal.
  • Département Adaptations du Vivant, Muséum National d'Histoire Naturelle, Paris, France.

ORCID-Profile: Gustavo Almeida-Silva

Zitieren

APA

Almeida-Silva, G., Ferreira, J., Santus, R., & Filipe, P. (2026). Phototherapy for Atopic Dermatitis in the Era of Biologics and JAK Inhibitors: Mechanisms, Protocols, Evidence, and Positioning. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag478

Vancouver

Almeida-Silva G, Ferreira J, Santus R, Filipe P. Phototherapy for Atopic Dermatitis in the Era of Biologics and JAK Inhibitors: Mechanisms, Protocols, Evidence, and Positioning. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag478

BibTeX
@article{AlmeidaSilva2026,
  author = {Almeida-Silva, Gustavo and Ferreira, João and Santus, René and Filipe, Paulo},
  title = {Phototherapy for Atopic Dermatitis in the Era of Biologics and JAK Inhibitors: Mechanisms, Protocols, Evidence, and Positioning},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  doi = {10.1093/ced/llag478}
}
Kostenlos starten →